


Our Pipeline

We are building a pipeline of *in vivo* and *ex vivo* therapies, as well as continuing to develop innovative modular platform capabilities.

| Program | Approach | Research | IND-Enabling | Early-Stage Clinical | Late-Stage Clinical | Partner |
|--------------------------------------|--|-------------|--------------|----------------------|---------------------|---|
| In Vivo | | | | | | CRISPR is the therapy |
| NTLA-2001: Transthyretin Amyloidosis | Knockout | | | | | LEAD Intellia THERAPEUTICS REGENERON |
| NTLA-2002: Hereditary Angioedema | Knockout | | | | | Intellia THERAPEUTICS |
| NTLA-3001: AATD-Lung Disease | Insertion | | | | | Intellia THERAPEUTICS |
| Hemophilia B | Insertion | | | | | LEAD REGENERON* Intellia THERAPEUTICS |
| Hemophilia A | Insertion | | | | | LEAD REGENERON* Intellia THERAPEUTICS |
| Research Programs | Knockout, Insertion, Consecutive Edits | | | | | Intellia THERAPEUTICS |
| Research Programs | Various | | | | | Intellia THERAPEUTICS REGENERON** SPARINGVISION |
| Ex Vivo | | | | | | CRISPR creates the therapy |
| OTQ923 / HIX763: Sickle Cell Disease | HSC | | | | | NOVARTIS Intellia THERAPEUTICS*** |
| NTLA-5001: Acute Myeloid Leukemia | WTI-TCR | | | | | Intellia THERAPEUTICS |
| Solid Tumors | WTI-TCR | | | | | Intellia THERAPEUTICS |
| Allo Undisclosed | Undisclosed | | | | | Intellia THERAPEUTICS |
| Other Novartis Programs | CAR-T, HSC, OSC | Undisclosed | | | | NOVARTIS Intellia THERAPEUTICS*** |



* Lead development and commercial party

** Rights to certain *in vivo* targets

*** Milestones & royalties only

CAR-T: Chimeric Antigen Receptor T cells

HSC: Hematopoietic Stem Cells

OSC: Ocular Stem Cells

Last updated January 6, 2022